Compare · CNSP vs SBFM
CNSP vs SBFM
Side-by-side comparison of CNS Pharmaceuticals Inc. (CNSP) and Sunshine Biopharma Inc. (SBFM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSP and SBFM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- CNSP is the larger of the two at $5.8M, about 3.0x SBFM ($1.9M).
- SBFM has been more active in the news (6 items in the past 4 weeks vs 2 for CNSP).
- Company
- CNS Pharmaceuticals Inc.
- Sunshine Biopharma Inc.
- Price
- -
- -
- Market cap
- $5.8M
- $1.9M
- 1M return
- -
- -45.57%
- 1Y return
- -
- -99.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 0
CNS Pharmaceuticals Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Sunshine Biopharma Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest CNSP
- SEC Form 10-Q filed by CNS Pharmaceuticals Inc.
- CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
- CNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
- JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
- CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
- SEC Form DEFA14A filed by CNS Pharmaceuticals Inc.
- SEC Form DEF 14A filed by CNS Pharmaceuticals Inc.
- Director Fisher Michal bought $10,000 worth of shares (2,000 units at $5.00) (SEC Form 4)
- CEO and President Levin Rami decreased direct ownership by 50% to 4,750 units (SEC Form 4)
Latest SBFM
- SEC Form S-1 filed by Sunshine Biopharma Inc.
- SEC Form DEFA14A filed by Sunshine Biopharma Inc.
- SEC Form 10-Q filed by Sunshine Biopharma Inc.
- SEC Form DEF 14A filed by Sunshine Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.
- SEC Form DEF 14C filed by Sunshine Biopharma Inc.
- Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
- SEC Form PRE 14C filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.
- SEC Form 8-K filed by Sunshine Biopharma Inc.